Cosmos Health targets FY2026 revenue >$180M and EBITDA >$20M; recaps 2023 milestones

Cosmos Health Inc.

Inaugural 2026 guidance: gross annual revenue over $180M and EBITDA exceeding $20M.
Completed three acquisitions in 2023: Cana Laboratories, I. Bikas GP assets, and ZipDoctor telehealth.
Nutraceutical brands Sky Premium Life and Mediterranation expanding into new sales channels and geographies.
Maintains robust balance sheet with negligible debt; CEO's personal investment now exceeds $15M.
Second phase of obesity product CCX0722 completed; clinical trials scheduled to start in Q4 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.